Clinical trial on efficacy and safety of eradication therapy for Helicobacter pylori infection to prevent gastric cancer.
Not Applicable
- Conditions
- atrophic gastritis with H. pylori infection
- Registration Number
- JPRN-UMIN000001434
- Lead Sponsor
- Department of Gastroenterology University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 1600
Inclusion Criteria
Not provided
Exclusion Criteria
1. gastric malignancies or gastric adenomas 2. gastroduodenal ulcers 3. allergy for medicine used in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gastirc cancer diagnosed by endoscopy
- Secondary Outcome Measures
Name Time Method safety
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie H. pylori eradication in preventing gastric cancer progression from atrophic gastritis?
How does H. pylori eradication therapy compare to standard-of-care treatments for atrophic gastritis in gastric cancer prevention?
Which biomarkers are associated with response to H. pylori eradication therapy in patients with atrophic gastritis?
What are the long-term adverse events of H. pylori eradication therapy in the JPRN-UMIN000001434 trial?
Are there combination therapies or alternative approaches to H. pylori eradication for gastric cancer prevention?